Children and adolescents with allergic asthma and serum IgE levels that exceed approved dosing ranges still benefitted from omalizumab, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
These benefits included improved lung function, reduced health care utilization and reduced use of oral corticosteroids (OCS), Claire E. Atkinson, MD, an allergy and immunology fellow in the division of allergy and immunology, department of pediatrics, at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and colleagues wrote in the